The serum FADS2 level in the NAFLD+CAD group (53.72 (15.02)) is significantly higher than that in the NAFLD group (7.93 (6.09)) (P < 0.05) and healthy people (6.94 (3.61)) (P < 0.05) (Figure 1). This evidence concerns the gene FADS2 and metabolic dysfunction-associated steatotic liver disease.